Haematopoietic stem cell transplants should be a second-line therapy for highly active MS

Abstract

Get full access to this article

View all access options for this article.

References

Coles

Twyman

Arnold

. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012; 380: 1829–1839.

Mancardi

Sormani

Gualandi

. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology 2015; 84: 981–988.

Nash

Hutton

Racke

. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report. JAMA Neurol 2015; 72: 159–169.

Atkins

Bowman

Allan

. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicentre single-group phase 2 trial. Lancet 2016. Epub ahead of print. doi: doi.org/10.1016/S0140-6736(16)30169-6

Pfender

Saccardi

Martin

. Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. Curr Treat Options Neurol 2013; 15: 270–280.

Rush

MacLean

Freedman

. Aggressive multiple sclerosis: Proposed definition and treatment algorithm. Nat Rev Neurol 2015; 11: 379–389.

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS – YES

Abstract

Get full access to this article

References